VIRTUAL 2020 ESMO congress

ZENITH20, a multinational, multi-cohort Phase 2 study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations

Mark A Socinski, MD

Executive Medical Director
Member, Thoracic Oncology Program
AdventHealth Cancer Institute
Orlando, FL, USA

DISCLOSURE INFORMATION

- Research Support (Institutional): Genentech, AstraZeneca, Daiichi-Sankyo, Spectrum, Takeda
- Speaker’s Bureau: Genentech, AstraZeneca, Guardant, Lilly, Jazz, Merck, BMS, Novartis, Bayer
- Steering Committee: Spectrum, Genentech

ZENITH20: Study Design



ZENITH20-2: Patient Characteristics

Disposition	N=90, n (%)
Treated	90 (100)
Ongoing	4 (4)
Age, median (range)	60 (25-86)
Female / Male, n	58 / 32
White /Asian / Others, n	70 / 12 / 8
Smoker / Non-Smoker, n	31 / 59
Number of therapies, median (range)	2 (1-6)
Chemotherapy only	22 (24)
Chemo / IO checkpoint inhibitors	41 (46)
Chemo / HER2 therapy / IO checkpoint inhibitors	17 (19)
Others	10 (11)
Mutations: A775_G776InsYVMA / Others, n	61 / 29

ZENITH20-2: Primary Efficacy

	As-Treated (N=90)	Evaluable (N= 74)
Objective Response Rate (ORR), n (%)	**25 (27.8)**	**26 (35.1)**
95% Confidence Interval	**18.9 - 38.2**	**24.4 - 47.1**
Disease Control Rate (DCR) , n (%)	63 (70.0)	61 (82.4)
Duration of Response (months) (range)	**5.1 (1 - 12.3+)**	**5.1 (1 - 12.3+)**
Median follow up of responders (months)	8.3	8.3
Median time on treatment (months) (range)	3.7 (0 - 16.6)	3.7 (0 - 16.6)
Progression-free Survival (months) (range)	5.5 (0 - 13.1+)	5.5 (1 - 13.1+)

Primary endpoint of ORR met (Lower bound of 95% CI >17%)

Waterfall Plot of Tumor Reduction (Best %Change from Baseline)



Summary of Exposure and Safety

	N=90, n (%)
Treatment-related AE	88 (98)
Treatment-related Serious AE	13 (14)
Dose interruptions	78 (87)
Dose reductions	70 (78)
AE related permanent discontinuation	11 (12)

Preferred Term (PT)	N=90, n (%)		
	Any Grade	Grade 3	Grade 4
Diarrhea	74 (82)	23 (26)	0
Rash	61 (68)	27 (30)	0
Stomatitis / Mucosal Inflammation	59 (66)	20 (22)	1 (1)
Paronychia	34 (38)	1 (1)	0
Pneumonitis	1 (1)	0	0

Summary and Conclusions

- Poziotinib met pre-specified study endpoint for HER2 exon 20 mutations
  - ORR of 35.1% in evaluable patients and 27.8% in all treated patients.
  - Tumor reduction in 74% patients
  - Median DOR of 5.1 months
- Manageable toxicity profile, in line with Cohort 1(EGFR) and other 2nd generation EGFR TKIs
  - Diarrhea and rash are most common
  - Only one Grade 1 pneumonitis in the heavily pretreated patients
- ZENITH20 is ongoing with alternative dosing and BID schedule

Acknowledgments

- We thank all the patients and their families
- We thank all the ZENITH20 investigators and the study teams at each participating center
- Authors:

  Socinski M, Cornelissen R; Garassino M; Clarke J; Tchekmedyian N; Molina J; Goldman R; Bhat G; Lebel F; Le X on behalf of ZENITH20 Study Group

VIRTUAL 2020 ESMO congress